Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지

Acute Oral, Intramuscular and Intravenous Toxicity Studies of Recombinant Interferon-$\alpha$2a in Sprague-Dawley Rats

  • Lee, Yong-Soon (Department of veterinary Public Health, College of Veterinary Medicine, Seoul National University) ;
  • Park, Jin-Sung (Department of veterinary Public Health, College of Veterinary Medicine, Seoul National University) ;
  • Che, Jeong-Hwan (Department of veterinary Public Health, College of Veterinary Medicine, Seoul National University) ;
  • Li, Guang-Xun (Department of veterinary Public Health, College of Veterinary Medicine, Seoul National University) ;
  • Kim, Tea-Won (Department of veterinary Public Health, College of Veterinary Medicine, Seoul National University) ;
  • Kim, Hyung-Sub (Department of veterinary Public Health, College of Veterinary Medicine, Seoul National University) ;
  • Park, Jie-Eun (Department of veterinary Public Health, College of Veterinary Medicine, Seoul National University) ;
  • Yun, Jun-Won (Department of veterinary Public Health, College of Veterinary Medicine, Seoul National University) ;
  • Kang, Kyung-Sun (Department of veterinary Public Health, College of Veterinary Medicine, Seoul National University)
  • Published : 2000.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Acute oral, intramuscluar, and intravenous toxicity studies of recombinant human interferon $\alpha$2$\alpha$(rhIFN $\alpha$2$\alpha$) were performed in Sprague-Dawley (SD) rats. SD rats were administered with doses of 31.25, 62.5, 125, 250 and 500 MIU/kg, respectively, and clinical signs, mortality and body weight changes were observed for 2 weeks. In all animals administered with rhIFN $\alpha$2$\alpha$, there was neither dead animals nor significant changes of body weights. In addition, no differences were found between control and treated groups in clinical signs and autopsy findings. Therefore, $LD_{50}$ of rhIFN $\alpha$2$\alpha$ was considered to be higher than 500 MIU/kg in SD rats.

Keywords

References

  1. Illustrated dictionary of immunology Cruse, J.M.;Lewis, R.E.
  2. N. Engl. J. Med. v.311 Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon Foon, K.A.;Sherwin, S.A.;Abrams, P.L.;Longo, D.L.;Fer, M.F.;Stevenson, H.C.;Ochs, J.J.;Bottino, G.C.;Schone-Berger, C.S.;Zeffren, J.;Jaffe, E.S.;Oldham, P.K.
  3. Ann. Inter. Med. v.93 Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma. and malignant lymphoma Gutterman, J.U.;Blumenschein, G.R.;Alexanian, R.;Yap, H.Y.;Buzdar, A.U.;Cabanillas, F.;Hortobagyi, G.N.;Hersh, E.M.;Rasmussen, S.L.;Harmon, M.;Kramer, M.;Pestka, S.
  4. Ann. Intern. Med. v.96 Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients Gutterman, J.U.;Fire, S.;Quesada, J.;Horring, S.J.;Leuine, J.F.;Aleanian, R.;Bernhardt, L.;Kramer, M.;Spiegal, H.;Colburn, W.;Trown, P.;Merigan, T.;Dziewanowski, Z.
  5. Ann. N.Y. Acad. Sci. v.350 Role of interferon in regulation of cyotoxicity by natural killer cells and macrophages Herberman, R.B.;Ortaldo, J.R.;Djey, J.Y.;Holden, H.T.;Jett, J.;Lang, N.P.;Rubinstein, M.;Pestka, S.
  6. The inerferon, Proc. R. Soc. Lond. (Biol.), B v.147 Virus interference Ⅰ. Isaccs, A.;Lindenann, J.
  7. Immunology Kuby, J.
  8. Proc. Natl. Acad. Sci. USA v.78 no.9 DNA sequence of a major human leukocyte interferon gene Lawn, R.M.;Gross, M.;Houck, C.M.;Franke, A.E.;Gray, P.V.;Goeddel, D.V.
  9. Proc. Natl. Acad. Sci. USA v.69 Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes Lindahl, P.;Leary, P.;Gresser, I.
  10. Blood v.68 no.2 Treatment of hairy cell leukemia with recombinant alpha-interferon Quesada, J.R.;Hersh, E.M.;Manning, J.;Reuben, J.;Keating, M.;Schnipper, E.;Itri, L.;Gutterman, J.U.
  11. Urology v.34 no.4 Suppl Role of interferons in the therapy of metastatic renal cell carcinoma Quesada, J.R.
  12. J. Immunol. v.125 Mode of action of interferon mediated modulation of natural killer cytotoxic activity: recruitment of pre-NK cells and enhanced kinetics of lysis Silva, A.;Bonavida, B.;Targan, S.
  13. N. Engl. J. Med. v.314 Chronic myelogenous leukemia: Hematologic remission and cytogenic improvement induced by recombinant alpha A inerferon Talpaz, M.;Kentarjon, H.M.;McCredie, K.B.